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Abstract
Background: The rising prevalence of type 2 diabetes underlines the importance of secondary strategies for the
prevention of target organ damage. While access to diabetes education centers and diabetes intensification
management has been shown to improve blood glucose control, these services are not available to all that require
them, particularly in rural and northern areas. The provision of these services through the Home Care team is
an advance that can overcome these barriers. Transfer of blood glucose data electronically from the home to the
health care provider may improve diabetes management.
Methods and design: The study population will consist of patients with type 2 diabetes with uncontrolled A1c
levels living on reserve in the Battlefords region of Saskatchewan, Canada. This pilot study will take place over
three phases. In the first phase over three months the impact of the introduction of the Bluetooth enabled glucose
monitor will be assessed. In the second phase over three months, the development of guidelines based treatment
algorithms for diabetes intensification will be completed. In the third phase lasting 18 months, study subjects will
have diabetes intensification according to the algorithms developed.
Discussion: The first phase will determine if the use of the Bluetooth enabled blood glucose devices which can
transmit results electronically will lead to changes in A1c levels. It will also determine the feasibility of recruiting
subjects to use this technology. The rest of the Diabetes Risk Evaluation and Management Tele-monitoring
(DreamTel) study will determine if the delivery of a diabetes intensification management program by the Home
Care team supported by the Bluetooth enabled glucose meters leads to improvements in diabetes management.
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Diabetes and its impact on the community
Diabetes is a systemic disorder resulting in abnormally
high blood glucose levels. These elevated levels impact
directly and indirectly on every part of the body. Diabetes
is the number one cause of end stage renal disease
(ESRD), preventable blindness, as well as a major cause of
premature heart disease, stroke, limb amputation and pre-
ventable hospital admissions[1]. Prevention of type 2 dia-
betes through primary control programs is society's
ultimate goal but current evidence indicates that this goal
is failing as rates of diabetes are rising rapidly. For exam-
ple in the Province of Ontario, prevalence rates of diabetes
rose by 69% to 8.8% in the 10 year period ending
2005[2]. Secondary prevention strategies to help reduce
the complication rate in this burgeoning population of
people with diabetes are desperately needed. Control of
blood glucose levels prevents new microvascular disease
and has recently been shown to have a legacy effect and is
a central focus of diabetes management programs[3], in
addition to the significant health benefits of blood pres-
sure and lipid control. The optimal degree of blood glu-
cose normalization has recently come into question.
While the ADVANCE study demonstrated a reduction of
microvascular but no significant reduction of macrovascu-
lar events with normalization of A1c to below 7.0%[4],
the ACCORD study, also targeting normalization of A1c
below 7.0%, found an elevated mortality and no reduc-
tion of cardiovascular events[5].
For those who develop diabetes, control of blood glucose
is important to prevent new microvascular target organ
damage. Blood pressure control prevents both micro and
macrovascular damage and lipid control macrovascular
changes. Two examples of health care initiatives to control
blood glucose levels in people with diabetes are now the
standard of care: The development and wide dissemina-
tion of the Canadian Diabetes Association's Clinical Prac-
tice Guidelines[1] and the widespread dissemination of
Diabetes Education and self-management[6]. The guide-
lines are evidence based and described in detail and, if fol-
lowed, would lead to control of blood glucose levels. The
guidelines are largely based on outcomes research carried
out in carefully controlled settings. The challenge is in
implementing them in a real world setting. Diabetes edu-
cation centers and Diabetes Educators are a necessary part
of the team for intensive diabetes management[6], but are
still not accessible to many people living in rural and
Northern areas. Furthermore there are only a few Diabetes
Education Centers designed specifically for First Nations
peoples. The closest in 2007 for the people living in
Northern Saskatchewan where this study takes place, is
more than a 3 hour drive away in Edmonton. However,
Home Care teams which provide home visits from nurses
and even dietitians and other members of the multidisci-
plinary team are able to access virtually all communities.
Traditionally Home Care teams have provided wound
and dressing care. However, the Home Care team can
include Diabetes Educators that can deliver evidence
based therapy as part of a chronic disease management
program for diabetes.
We believe that this study protocol has relevance with
respect to the development of a new community-based
approach to the control of blood glucose. We have
recently demonstrated that the Home Care team (which
provides supportive care provided in the patient's home
by healthcare professionals) of the Battlefords Tribal
Council Indian Health Services, can improve blood pres-
sure control using a chronic disease management model
for multiple drug therapy[7]. We believe that a chronic
disease management model linking the Home Care Team
including Diabetes Educators[6] with their clients and the
primary care providers to try to bring A1c to 7.0% can
improve blood glucose control safely. Combining ele-
ments of chronic disease management including provider
education, patient education, clinical practice guidelines,
decision support and disease measurement is expected to
lead to lasting improvements in diabetes management[8].
Use of the Bluetooth enabled glucose meters may be able
to enable diabetes intensification in a safe and effective
manner, allowing the Home Care team to review their cli-
ents with access to their client's self monitored blood glu-
cose results.
Diabetes, First Nations and kidney disease
End stage kidney disease (ESRD) comprises an enormous
public health burden, with an incidence and prevalence
that are increasing alarmingly. For example, between
1998 and 2002, the prevalence of ESRD in Canada
increased 33%, while the incidence increased 17%[9]. In
Canada, 4.7% of all new dialysis starts are identified as
Aboriginal while in the province of Saskatchewan 19.7%
of new dialysis starts are identified as aboriginal[10]. In a
study of the aboriginal population of Australia, Hoy
found an incidence of ESRD in this population ten times
greater than the incidence in the general population [11].
First Nations Peoples are at higher risk for ESRD, largely
due to diabetes [12-15]. The prevalence of diabetic neph-
ropathy is much higher among Aboriginal Canadians
than in the general population, with rates ranging from
25–60%[16,17]. Morrison [18] noted that in the First
Nations population of the Sioux Lookout Zone, North-
western Ontario, that children as young as five years of age
have been diagnosed with type 2 diabetes. With diabetes
occurring at increasingly younger ages, ESRD is going to
become more prevalent in a younger age group with dia-
betes[16]. Canada is not alone in this respect as the prev-
alence of kidney disease in the Australian Aboriginal
population with diabetes is approaching 50%[19,20].
Hypertension in those with diabetes is a strong predictor
of death from diabetic nephropathy [21]. The etiology ofPage 2 of 11
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multifactorial in nature, including social and societal
issues endemic to Western society and those specific to the
aboriginal community, as well as genetic factors and are
beyond the scope of this project [22].
Unless early and sustained blood glucose control can be
achieved, higher rates of diabetes with earlier age of onset
will result in more frequent complications from diabetes
with resultant higher costs to quality of life and the health
care system. Linked to the rising rates of diabetes in Abo-
riginals are risk factors for and higher rates of cardiovascu-
lar disease [23-32]. Kidney disease, now recognized as a
significant marker of cardiovascular disease [33-35], may
be in part responsible for this and blood glucose control
has been demonstrated to be effective in reducing the pro-
gression of kidney disease in the setting of diabetes[36].
However, medication alone is insufficient to achieve con-
trol. London[37] has demonstrated, in an Australian Abo-
riginal diabetes study, that health information must also
incorporate the contemporary beliefs of the community.
Implementation of treatment programs with First Nations
peoples must be carried out with sensitivity to cultural
mores and beliefs [38-42].
Intensification of Diabetes Management. The current
Canadian Diabetes Association Clinical Practice Guide-
lines recommend similar glycaemic goals for both type 1
and type 2 diabetes and define optimal glycaemic control
as an A1c < 7.0% [43]. A stepwise approach is advocated
with initial therapy consisting of lifestyle changes fol-
lowed by the addition of one or more oral hypoglycemic
agents, followed by the addition of/replacement by insu-
lin. Given that diabetes is a progressive disease, the need
for insulin in people with type 2 diabetes, will continue to
rise. A team approach is also recommended; the person
with diabetes is at the core of this team with the primary
care physician, diabetes nurse educator, dietitian, diabetes
and other specialists, and others also being members. The
CDA Clinical Practice Guidelines recommend a A1c <
7.0%. Although A1c is considered to be the best measure
of overall glycaemic control, blood or capillary glucose
levels are still important to obtain in order to safely and
effectively manage the doses of the oral hypoglycemic
agents and insulin. This can best be done by having the
person with diabetes perform self-monitoring of blood
glucose (SMBG) at various times of the day.
There is now evidence in both type 1 as well as type 2 dia-
betes that improved glycaemic control will reduce the
microvascular complications of diabetes[44]. An epidemi-
ologic analysis of the UKPDS[45] showed that there is no
threshold for benefit when it comes to glucose lowering,
and that any reduction in A1c is associated with reduced
risks for both micro- and macrovascular disease. In their
analysis, every 1% decrease in A1c was associated with a
25% reduction in risk for myocardial infarction[45]. The
ADVANCE study demonstrated a reduction of microvas-
cular events with normalization of A1c to below 7.0%[4].
The ACCORD study which targeting aggressive normaliza-
tion of A1c in patients with longstanding diabetes, found
an elevated mortality in the intensive group which tar-
geted normalization of blood gluocse[5]. The goal of dia-
betes intensification in this study is to reduce the risk for
the complications of diabetes by controlling blood glu-
cose safely.
Rates of use of insulin and hypoglycemia, evidence from 
clinical trials
Studies of glycaemic control in people with type 1[46] and
type 2[44] diabetes have shown improvements in compli-
cations such as the progression of kidney, eye and heart
disease. Achieving control of blood glucose requires
adherence to lifestyle changes as well as titration of medi-
cations, including the initiation of insulin therapy and the
titration of the insulin dose. The intensive treatment
group of the STENO-2 study led to over 50% being started
on insulin with an average dose of 62 units per day[47].
Of interest, a greater proportion of the usual care group
was started on insulin and there was a trend to higher
doses. The glycaemic target in the intensive arm of the
STENO-2 study was an A1c of 6.5%, compared to about
7.5% in the control arm. Despite lower blood glucose lev-
els attained in the intensive treatment group, there were
fewer major hypoglycemic complications (eg. impaired
consciousness which required help from another person)
in the intensive treatment compared to the control group
(just under 1% vs. 2% per patient year respectively)[47].
In the UKPDS 33 study the rates of major hypoglycemic
episodes per year were also relatively low, 0.7% with con-
ventional treatment, 1.0% with chlorpropamide, 1.4%
with glibenclamide, and 1.8% with insulin[48,49]. Fear of
the complications of insulin therapy, particularly
hypoglycemia, by both patients and health care workers,
is one of the major barriers to implementing intensifica-
tion of diabetes management. The ability to monitor
blood glucose levels remotely in people who are having
their diabetes medications adjusted may go a long way to
providing the same kind of safety net for diabetes manage-
ment that was the rationale for managing diabetes in the
hospital setting years ago.
The Battlefords Tribal Council Indian Health Services and 
approach to diabetes
The Battlefords Tribal Council Indian Health Services is a
First Nations owned and operated Health Services organi-
zation established over 26 years ago. The Board of Direc-
tors consists of the seven Chiefs of the Battlefords Tribal
Council First Nations. The population of each of the seven
communities ranges from 500 to 700 people for a total
population of 4,121 persons living on reserve[50]. North
Battleford serves as the central base for the delivery ofPage 3 of 11
(page number not for citation purposes)
BMC Endocrine Disorders 2009, 9:13 http://www.biomedcentral.com/1472-6823/9/13health services for the seven communities. All communi-
ties are within 90 kilometers of medical facilities. The cul-
ture is primarily Cree, and Cree and English languages
predominate. A survey completed in 1999 found that dia-
betes, heart disease, cancer and high blood pressure were
the top four most serious health-related problems for the
community[50]. Diabetes was found in 22% of
adults[51].
The Home and Community Care Diabetes Education Pro-
gram has a ten year history and has been constantly evolv-
ing during that time. The Program encompasses all levels
of prevention: primary, secondary and tertiary. Program
staff includes one Home Health Aide and Registered
Home Care Nurse in each community. A dietitian, diabe-
tes nurse educators and exercise therapist serve all com-
munities. Four of the staff members (1 dietitian and 3
nurses) have received Canadian certification as Diabetes
Educators. All program development considers cultural
appropriateness; in addition, nine staff members are flu-
ent in the Cree language.
The Home Care team has always had a primary preven-
tion component and this has been significantly aug-
mented in the last three years through the Aboriginal
Diabetes Initiative that has helped to increase community
access to fresh fruits and vegetables through a Good Food
Box program; a granting process to support community-
based initiatives (walking groups, healthy snacks, cooking
groups); a training program for staff who cook meals in
the schools; and, a healthy lifestyles newsletter. Secondary
prevention is addressed through diabetes education pro-
vided to people with diabetes and members of their fam-
ily. Another component of client education is foot
assessment and care; nurses hold regular foot care clinics.
Prior to the DreamTel program, the Home Care team did
not provide diabetes treatment or management. Instead,
staff members referred clients to their family physician
and advocated for treatment, with referral to specialists as
needed. Prior to the DreamTel program, for the initiation
of insulin in community members with type 2 diabetes, it
was standard practice for primary care providers to
arrange for admission to hospital for insulin initiation.
Diabetes intensification was coordinated through the Dia-
betes Education Center at the Battlefords Hospital. How-
ever, its distance from people living on reserve with
diabetes limited their access for repeated visits and ongo-
ing education and treatment. At the time the DreamTel
program was initiated, there were no diabetes specialists
in Northern Saskatchewan, so that there was no backup
for primary care providers. All of this added to the risk for
clinical inertia for diabetes intensification and the initia-
tion of insulin.
The ability to accurately monitor blood glucose results
with self monitoring of blood glucose (SMBG) is pivotal
to the success of managing and controlling blood glucose
levels in people with diabetes on insulin. Glucose meters
in current use require the user to record the displayed
result into a logbook along with the timing of the reading.
This allows cumulative readings to be analyzed for pat-
terns. Barriers to health care workers receiving accurate
logbooks include the ability and willingness of the person
using the glucose meter to record the results accurately
and to bring the logbook with them to appointments with
health care providers. Evidence provided by glucose
meters with memories has demonstrated that the record-
ing of results into logbooks may not be accurate[52], even
when glucose meters users know that their device is also
recording the levels. Furthermore, health care providers
only get access to the information in the logbook or that
stored within the glucose meter during patient or client
visits. This may lead to prolonged episodes of dysglycae-
mia before the client can receive medical attention. Blue-
tooth enabled glucose meters facilitate the downloading
of the results to a secure electronic format available to
health care providers via a web interface. This may help to
eliminate the effects of geography and will allow the
potential for more frequent health care monitoring of
SMBG. The health care team can arrange for more fre-
quent monitoring during titrations of drug therapies or
the initiation of insulin. Patients with questions about
their management will be able to initiate a health care
provider review of their results by phone-call without gen-
erating a visit.
The ultimate goal of the DreamTel project is to develop a
process for initiating insulin therapy in the community
setting including intensification of diabetes management
in a culturally appropriate manner. If successful, the leg-
acy of the project will be a change in medical practice in
the community with the introduction of a chronic disease
management model for type 2 diabetes management,
where primary care physicians can consult with the Home
and Community Care team for initiation of insulin ther-
apy in the community as well as intensification of diabe-
tes therapy.
Methods and design
The DreamTel project is designed to be carried out in 3
phases. In the first phase, the new technology will be
introduced to volunteer subjects with uncontrolled type 2
diabetes. The second phase includes the development and
implementation of a nurse directed medical management
model for type 2 diabetes to allow a change in practice
within the community. The goal is to allow primary care
physicians in the community to refer patients to the
Home Care team for initiation of insulin and diabetes
intensification. This process involves health care provider
education, the development of algorithm driven proto-
cols based on clinical practice guidelines, patient educa-
tion and disease measurement. In the third and finalPage 4 of 11
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the device 80% of the time will be invited to participate in
diabetes intensification with oversight from their primary
care physicians.
Phase 1: Introduce the Bluetooth-enabled glucose meters 
into the community
Experimental Design. The target populations for the
DreamTel study are participants with Type 2 diabetes and
uncontrolled blood glucose levels with A1c levels in
excess of 7.0%. Fifty subjects are targeted in the pilot
study. Clients willing to participate in the program who
have uncontrolled diabetes based on A1c levels above tar-
get will receive information on the use of the Bluetooth
enabled device and will be consented into the project.
They will then have the device installed into their home
and receive training on its use from the Home Care team.
Technical support is available from the sponsor. For the
first phase, lab testing for A1c takes place at initiation of
the device and after three months. Subjects will be identi-
fied by their primary care physician or by the Home Care
team as needing diabetes intensification. Thus they will
constitute a convenience sample. Subjects will be trained
in the use of the glucose meters but do not have to be tak-
ing insulin on enrollment. All will be trained on the Blue-
tooth technology. The LifeStat service is an Integrated
Communications Technology to capture physiological
data that is transmitted via Bluetooth to an aggregation
device located at the point of care. The aggregation device
can be a cell phone but in the DreamTel study due to
insufficient local coverage a Bluetooth/Analog modem
with the local telephone will be used. The data is then for-
warded to a secure hosting center by standard telephone
network. The information is then accessed by users with
the appropriate credentials through a care giver portal.
All subjects receiving the device will have a multi-discipli-
nary team diabetes assessment with standard diabetes
screening tests including a baseline A1c level and agree to
follow-up lab work on a three-month basis throughout
the duration of the study. Each study subject will receive
training in how to use the device and will be instructed on
how to indicate that a test run was a validation test or
another person's sample. Subjects will be instructed to use
the results of the testing to manage their diabetes accord-
ing to the education they received in light of food intake
(or lack of), physical activity and whether medication had
been taken. The client will be taught how to use the device
and how to demonstrate that they were able to accurately
use it. Data forwarded to the web server will be displayed
through the portal graphically and include summary sta-
tistics. Data can also be printed by the patient's health care
providers and could became part of the client's medical
record. All consenting subjects will be asked to notify their
primary care physicians that they are using the new device
during regularly scheduled visits. Their physicians will
also receive information packages from the Home Care
team on the study and will be invited to participate in
local Continuing Health Education programs on the study
and the technology used. To determine whether the instal-
lation of the LifeStat device linked to the patient's tele-
phone line impacts on blood glucose control, the A1c
level at baseline (prior to its installation) will be com-
pared to the three-month value. Typically A1c levels
remain stable over short periods of time, rising over a
period of years[45].
To provide data on whether the blood glucose monitoring
was before or after a meal, a teleprompt will be delivered
to the client's phone. When a blood glucose result is
received by the central server at SaskTel's central office in
Saskatoon, Saskatchewan, an automatic teleprompt will
call requesting a response as to the relationship between
the test result and the last food intake. The teleprompt was
developed in English and in Cree. Patients will be trained
in its use. Each patient's impression of the teleprompt sys-
tem will be addressed in questionnaires administered
after the first 3 months of its use. Learning challenges will
be collected as qualitative data to record the duration of
time spent teaching and to record the challenges faced.
Another objective for the first three months of use is to
compare data from three different sources; data transmit-
ted by the device and stored on the web site, data stored
on the device itself and the patient's log book, noting dis-
cordant values. Data is to be presented as the proportion
of results recorded accurately. The frequency of monitor-
ing based on data from the electronic output is to be
assessed for the entire period.
Phase 2: Development of a Chronic Disease Management 
model for initiation of insulin in the community and 
intensification of blood glucose control
The medication algorithm is broken into stages and can
be found in Additional File 1: Initiation of metformin, ini-
tiation of sulphonylurea, initiation of thiozolidendiones
and finally initiation of insulin followed by multidose
insulin. A plan of management for diabetes intensifica-
tion will be prepared for each patient based on their stage
at their enrollment into phase 3, the treatment phase of
the study. This plan will describe the dietary and lifestyle
intervention they will receive as well as the planned stage
for medication for the diabetes intensification. Prior to
initiating each stage of medical therapy, a letter will be
sent to the Primary Care physician including the results of
the blood glucose monitoring. The letter will indicate the
stage of diabetes intensification recommended and will
include a standardized Home Care order set for that stage.
The order sets were reviewed with some of the local pri-
mary care physicians during invited continuing educationPage 5 of 11
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Care physician has reviewed this and signed the order set
this stage of diabetes intensification will begin. When the
stage of intensification of diabetes has been completed
the Home Care team will notify the Primary Care physi-
cian. If the patient has achieved diabetes targets they will
be maintained at this stage. If they have not achieved tar-
get then the orders for the next stage will be sent to the Pri-
mary Care physician and the patient assessed for the next
stage.
Algorithms developed for diabetes management were
developed based on clinical practice guidelines and
reviewed with experts in diabetes management. For self
monitoring of blood glucose[1], the goal is a minimum of
four times daily, two days per week for those on or starting
insulin. Medication will be introduced in a stepped fash-
ion for those on diet therapy alone starting with met-
formin followed by a sulphonylurea (gliclazide, as it is
better tolerated in patients that develop kidney disease
than others)[53], thiazolidendiones (TZD's) will be
added if sulphonylureas have failed. Pioglitazone (Actos)
was chosen for use as it is a once daily preparation. This
step was added prior to the controversy over rosiglita-
zone[54]. The algorithm for diabetes intensification to be
carried out by the Home Care team was incorporated into
a standardized order form for the primary care physician
to approve. The study team in partnership with the pri-
mary care physician will be responsible for assessing con-
traindications to the algorithms.
The initiation of insulin is often frightening for patients
and a program of education and an algorithm for the
introduction of insulin were developed. At all times, the
primary care physician will be kept in the loop as part of
a management model. After Home Care visits, reports on
study letterhead will be faxed or mailed to the primary
care physician. In addition, a system of graded alerts
developed by the Home Care team including the use of
the existing Provincial emergency Health Hotline and
medical backup will be used in the study.
The goal of this phase of the program is to facilitate a
change of practice to improve diabetes management over
the long term. Physicians and the Home Care team need
to become integrated and systems developed to do this.
The hope is that following the study, patients who require
diabetes intensification will be identified by the physi-
cian, the Home Care team and possibly by patients them-
selves. The Primary Care Physician would then initiate the
process by signing a completed Home Care referral form
for the initiation of intensification of diabetes manage-
ment. This will initiate a visit by the Home Care team
(nurse or dietitian).
Following three months with the device, if patients are
testing at 80% of the target for measurement, they will be
enrolled in the next phase of the program and receive dia-
betes intensification therapy. At this point, following the
first phase, patients willing to participate in the program
will received a physical exam and assessment of their cur-
rent diabetes status and medications with a specialist and
a determination on which part of the diabetes intensifica-
tion algorithm they are in.
In the Province of Saskatchewan there is a billing code for
the supervision of diabetes intensification. Educational
sessions for the primary care physicians will include the
rationale for the DreamTel study, a review of the protocol
itself and information on this billing code and its appro-
priate use for the management of these patients. It is a goal
of the DreamTel study that the Primary Care physicians
will be able to continue to work with the Home Care team
for the intensification of diabetes management after the
project has been completed.
Home care referral forms were developed for the primary
care physicians. It was planned that if the primary care
physician did not want the Home Care team to do the
intensification of diabetes management according to the
planned algorithm that the subjects would be followed as
a control. If the primary care physician directs the Home
Care team to manage the patients in a similar fashion,
only using different medications from the algorithm,
based on patient specific factors, these patients will
remain in the study. Referrals to the local diabetes educa-
tion centre will be tracked if any occur. The commence-
ment date for intensification will be recorded.
Intensification is defined as increasing the dosage of a
medication, adding another medication or initializing
insulin according the algorithm for intensification.
For clients on oral anti-hyperglycemic agents, designated
RN(s) who are part of the Home Care team will adjust
these medications based on the protocol. Off-standard sit-
uations will be reviewed with one of the specialist study
physicians.
The study endocrinologist (RL) will regularly review the
medication adjustments for randomly selected clients as a
quality control procedure. The Diabetes Educators will be
able to review off-standard situations with him for advice
and support. The web-based glucose readings will foster
this process as the Diabetes Educator and endocrinologist
will be able to view the client records and adjustment con-
currently via the Internet. Time has been set aside for this
on one weekday morning each week by teleconference.
Development of the nurse protocol for the proposed
study is based on the adaptation of the provincial tem-Page 6 of 11
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tor.
Phase 3: Achieve better control of blood glucose levels
Rationale. Based on the success of the DREAM study
where a chronic disease management model resulted in
improved blood pressure control[7], the DreamTel study
hopes to demonstrate that a chonic disease management
program can improve glycemic control in First Nations
People with diabetes.
Experimental Design: The main intervention will be
applied to the treatment group and will consist of diabetes
management intensification including a stepped drug
protocol algorithm for pharmacologic management of
blood glucose including the addition of insulin when
indicated, diet and lifestyle education, with the long term
goal of achieving A1c levels of ≤ 7.0%. (see Additional File
1)
The study is designed as a pilot consisting of fifty subjects.
Subjects entering this phase of the study will have type 2
diabetes and will have used the LifeStat blood glucose
monitoring device for 3 months. Subjects will have com-
pleted at least 80% of all recommended glucose meters
readings and will have been agreeable to intensification of
diabetes according to the treatment algorithm. Diabetes
intensification includes as needed, the initiation of oral
hypoglycemic agents, the addition or increase of dosage of
oral hypoglycemic agents and the initiation and dose
titration of insulin. A1c levels will be drawn on a three-
monthly basis. If fewer subjects than anticipated make it
through phase 1 and are eligible for phase 3, additional
subjects will not be recruited. As this is a pilot study, the
reasons that fewer subjects than expected are able or will-
ing to enroll into phase three will be explored.
All patient information specific to diabetes management
from each Home Care visit to implement the intensifica-
tion protocols will be forwarded to the patient's family
physician. Follow-up with the patient's primary care phy-
sician will be requested by the Home Care team with each
medication change to ensure that they are aware of the
patient's new treatment status, and that it corresponds to
their desired treatment goals for that patient. The Home
Care team will be responsible for attempting to maintain
ongoing contact with their clients if their clients accept
that contact. Participants will be provided with snacks and
meals as well as health-promotion materials part of cur-
rent protocols. Additionally the study sponsor provided
gifts such as t-shirts and mugs for study visits to see the
study investigators, part of preexisting health promotional
activities.
The initial assessment will include lab testing and histori-
cal information to address risk factors for cardiovascular-
renal disease. The results of all testing will be forwarded to
the primary care physician; subsequently, protocol-driven
therapy for blood sugar control will begin. Medication
doses and compliance will be closely monitored and pre-
scriptions will be adjusted, as necessary. In the DREAM3
study, 45% of subjects had A1c levels ≥ 8.0%[7].
This investigation will be conducted in North Battleford,
Saskatchewan. The DreamTel nurse coordinator will be
based at the Battlefords Tribal Council Health Care serv-
ices in North Battleford and will coordinate all aspects of
the study under the supervision of Joan Wentworth. Dr.
Lewanczuk will be responsible for the diabetes manage-
ment algorithm. Data collection and management will be
coordinated by Dr. Sheldon Tobe. A data clinical research
assistant, based in Toronto, will be responsible for the
monitoring, data collection and data entry. Statistical
analysis will be performed at the Institute for Clinical
Evaluation (ICES) in Toronto.
Inclusion criteria
Type 2 Diabetes with baseline A1c ≥ 7.0% on diet or med-
ical therapy with no history of diabetic ketoacidosis.
Patients must be greater than or equal to 18 years of age.
Written informed consent must be obtained prior to
admission to this study.
Analytic procedures and sample size calculation
This is a pilot study that will compare, in a before and after
methodology, the intervention of diabetes intensification
on the primary response variable of blood glucose level
(A1c) measured at baseline and at 6 months. The pilot
study will also determine the ability to enroll patients into
the study and determine how many are able to maintain
an 80% adherence rate to the use of the glucose meter four
times daily at least twice weekly. This is also a goal of
phase 3 of this study. See Additional file 2 for statistical
design considerations.
Initiation of Diabetic Medication Treatment: The goal of
Intensification therapy is A1c <7.0%. Patients in the usual
care arm will continue to see their primary care physi-
cians. Therapy in the treatment group will be initiated
with the goal to bring the fasting plasma glucose ≤ 6
mmol/L and in insulin treated patients, pre-meal glucose
concentrations of 4–7 mmol/L.
Safety and Interim Monitoring. Drug therapy may be
interrupted at any time during the trial if further evidence
for more appropriate drug therapy becomes available. All
drugs used in this trial are available in regular clinical
practice. Women of child-bearing potential must have a
negative urine pregnancy test prior to receiving study
medication. Patients will be asked for adverse events from
the last visit related to hypoglycemic episodes and these
data recorded. In the UKPDS 33 study the rates of majorPage 7 of 11
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tional treatment, 1.0% with chlorpropamide, 1.4% with
glibenclamide, and 1.8% with insulin [48,49]. Severe
hypoglycemia defined as needing the assistance of
another person, or coma, will be tracked, as will diary-
recorded instances.
Case report forms, confidentiality, data security and mon-
itoring. Case report forms will be completed by the study
nurse in Saskatchewan and faxed to the coordinating cen-
tre in Toronto after all patient identifiers have been
removed; data monitoring will be completed on each
visit. The original forms will be kept on file at the Battle-
fords Tribal Council Indian Health Services. All data is
owned in collaboration with the Battlefords Tribal Coun-
cil Indian Health Services. All work for publication from
this data will be shared with this group prior to submis-
sion and requests for aggregate data will be honored as
quickly as resources permit. At all times the Investigators
have the final responsibility for the accuracy and authen-
ticity of all clinical data entered on the CRF's. The study
will be conducted according to the Battlefords Tribal
Council Indian Health Services Ethical Guidelines for
Research and the principles of Ownership, Control,
Access, Possession[55]. The Data Coordinator/Monitor
will conduct site visits four times annually at a mutually
agreed upon time for the purpose of auditing the study.
The local investigator and clinical coordinator agree to
allow the monitoring of the clinical supplies storage area
and study documentation.
Approvals. The Battlefords Tribal Council Indian Health
Services Inc has passed a Tribal Council Resolution
approving the implementation of the DreamTel study.
Ethics approval has been obtained from the Sunnybrook
Health Sciences Centre and the BTC Research Ethics
Boards. (see Additional file 3)
Study subjects will be followed from study entry until
study completion (18 month study protocol from the start
of phase 1). The primary outcome of this phase of the
study is the A1c after 6 months. A1c results collected
beyond this will be analyzed if there are sufficient sub-
jects. Subjects may withdraw from the study at any time.
Subjects who refuse or are unable to adopt the recommen-
dations of diabetes intensification management will be
followed in an intent-to-treat fashion.
Discussion
Our long term goal is to achieve targets for blood glucose
and blood pressure in people with diabetes as outlined by
clinical practice guidelines[1] and thus to prevent target
organ damage. The specific hypothesis behind the pro-
posed research is that diabetes care in First Nations people
can be improved by the involvement of the Home Care
team with the patient, the primary care physician and the
specialist in a chronic disease management program. The
goal is to develop and implement a Chronic Disease Man-
agement Program for diabetes intensification which
includes the four factors that have been shown to work
when combined together; provider education, patient
education, clinical practice guidelines and disease meas-
urement [56]. In this study, diabetes intensification will
be supported by emerging technology, specifically Blue-
tooth-enabled glucose meters and blood pressure moni-
tors, capable of transmitting their data to a web
environment in tabulated and graphical format available
for remote viewing. This hypothesis is based on the fol-
lowing observations and evidence: First, despite current
clinical practice guidelines and evidence-based practice by
the medical community, including family physicians and
the Home Care team, blood glucose control in general
and in the First Nations community specifically is not
meeting targets [1,57]. Poor control of blood glucose in
type 2 diabetes dramatically increases the risk of heart dis-
ease, stroke, vascular limb loss, blindness, kidney disease
and the need for dialysis. Control of blood glucose levels
prevents these complications. Second, the intensification
of diabetes control including the initiation of insulin is
not easily done during a regular primary care visit. The
lack of intensification of diabetes management in people
with poorly controlled diabetes has been referred to as
'clinical inertia' [58]. While subjects referred to specialists
have somewhat better control of diabetes, more than 50%
still failed to have intensification of diabetes management
within four months of a lab report showing a high level of
A1c [58]. Diabetes specialists are not accessible to all pri-
mary care practitioners. Third, multidisciplinary care can
overcome clinical inertia, even in difficult practice set-
tings. We recently demonstrated, for intensification of
blood pressure control, that a program delivered by the
Home Care team could achieve target blood pressure in
almost 50% of patients [7]. In addition, this program,
which was closely linked with the primary care commu-
nity and hypertension specialists, improved communica-
tion and health care provider satisfaction with the
management of this condition. Fourth, the emerging tech-
nology of Bluetooth-enabled devices and secure web
based monitoring logs allows health care providers for the
first time to remotely monitor progress, providing a
higher level of confidence in self blood glucose monitor-
ing (SBGM) and blood pressure results. The specific aims
are designed to provide a comprehensive assessment of
the impact of the introduction of this program.
This study has limitations inherent to its design as a pilot
and reliance on a convenience sample of subjects. Further,
with a limited number of family physicians, it is possible
that a change of practice may reduce the number of sub-
jects with poorly controlled diabetes. This will also makePage 8 of 11
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some sort of cluster design at the level of the primary care
physician or even community.
Diabetes is among the most debilitating of all chronic ill-
ness. First Nations people living on reserve have high
prevalence rates of diabetes and those ill with this condi-
tion are then challenged by the long distances they must
travel to receive specialized diabetes management. Fur-
thermore, family physicians are now challenged by a lack
of specialty care for complex diabetes management issues.
We believe that the Home Care team can bridge these
treatment gaps using available technology including
remote specialty consultation when needed. Home Care
nurse management of blood glucose control will lead to
earlier identification of people who are at risk of the com-
plications of high blood glucose and the Home Care
multidisciplinary team will lead to greater control of
blood glucose. Accomplishing the specific aims outlined
in this proposal will provide the foundation required to
roll out this methodology to rural and Northern commu-
nities.
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